Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease

用于控制炎症性肠病的 CD40 信号小分子抑制剂

基本信息

  • 批准号:
    10673011
  • 负责人:
  • 金额:
    $ 35.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Despite advances in the treatment of inflammatory bowel disease (IBD), many patients fail to respond to therapy. Thus, there is a need to find new therapeutic approaches against IBD. The CD40-CD154 pathway is a known target against IBD and other inflammatory disorders. Clinical trials indicated that CD40 blockade with anti-CD154 antibodies reduced inflammation. However, the anti-CD154 antibodies caused thrombosis (unrelated to inhibition of CD40). Moreover, other approaches to cause global inhibition of CD40 are predicted to increase the risk of opportunistic infections. Identification of a strategy to inhibit CD40-induced inflammation that does not induce thrombosis or opportunistic infections can be a major advance in the treatment of IBD. We uncovered that blocking the interaction between CD40 and an intracellular adaptor protein inhibits pro- inflammatory responses induced by CD40 while leaving protection against an opportunistic pathogen intact. We identified a small molecule that binds the adaptor protein, blocks CD40 signaling, reduces pro- inflammatory responses in vitro and diminishes intestinal inflammation in mouse models of IBD. The compound did not impair resistance against an opportunistic pathogen. The compound has suboptimal solubility and microsomal stability. While some analogs designed to date showed some improvement in solubility or microsomal stability, further optimization is necessary. The objective of this application is to develop an optimized inhibitor that will be tested in mouse and human IBD systems. The central hypothesis is that a potent analog with improved solubility and microsomal stability will optimally block CD40 signaling, and markedly suppress inflammation in mouse models of IBD as well as CD40-driven inflammatory responses in intestinal cells from patients with IBD. To test this hypothesis, we will design and generate analogs of the compound, test their properties, perform signaling studies in reporter cells and intestinal cells and test the lead inhibitor in animal models of IBD. In the first specific aim we will use structure activity relationships with the aid of a docking model to design and generate analogs of the compound in order to improve solubility and microsomal stability. We will examine their ability to inhibit CD40 signaling and their affinity for the adaptor protein. In the second aim, we will test the most potent analogs to determine if they inhibit CD40 signaling in vivo. In the third aim, we will determine if the lead analog reduces intestinal inflammation in mouse models of IBD and inhibits CD40-induced expression of inflammatory molecules in intestinal cells from IBD patients. The proposed work may lead to a new strategy to treat IBD based on a novel approach to inhibit CD40 signaling.
项目总结 尽管炎症性肠病(IBD)的治疗取得了进展,但许多患者对 心理治疗。因此,有必要寻找新的治疗方法来治疗IBD。CD40-CD154途径是一种 已知的针对IBD和其他炎症性疾病的靶点。临床试验表明,CD40阻断与 抗CD154抗体可减轻炎症。然而,抗CD154抗体导致了血栓形成 (与抑制CD40无关)。此外,还预测了导致CD40全局抑制的其他方法 以增加机会性感染的风险。确定一种抑制CD40诱导的炎症的策略 这不会导致血栓形成或机会性感染,这可能是IBD治疗的一大进步。 我们发现,阻断CD40和细胞内适配子蛋白之间的相互作用会抑制前... CD40诱导的炎症反应,同时对机会性病原体的保护完好无损。 我们发现了一种小分子,它能结合接头蛋白,阻断CD40信号,减少前... 体外炎症反应和减轻IBD小鼠模型的肠道炎症。该化合物 不会削弱对机会性病原体的抵抗力。 该化合物具有次佳的溶解度和微球稳定性。虽然到目前为止设计的一些类似物 在溶解度或微球稳定性方面有所改善,有待进一步优化。目标是 这一应用的目的是开发一种优化的抑制剂,将在小鼠和人类IBD系统中进行测试。 中心假设是,一种具有更好的溶解性和微粒体稳定性的强效类似物将是最佳的 阻断CD40信号,并显著抑制IBD小鼠模型的炎症以及CD40驱动的炎症 炎症性肠病患者肠道细胞的炎症反应。为了验证这一假设,我们将设计和 产生化合物的类似物,测试它们的性质,在报告细胞中进行信号研究,以及 并在IBD动物模型中检测铅抑制物。在第一个具体目标中,我们将使用结构 借助对接模型设计和生成化合物的类似物的活性关系 以提高溶解度和微粒体稳定性。我们将研究它们抑制CD40信号的能力以及它们的 对接头蛋白的亲和力。在第二个目标中,我们将测试最强大的类似物以确定它们是否 体内抑制CD40信号转导。在第三个目标中,我们将确定铅类似物是否减少肠道 炎性反应抑制CD40诱导的炎性分子在IBD小鼠模型中的表达 IBD患者的肠道细胞。这项拟议的工作可能导致一种新的治疗IBD的策略,该策略基于一种新的 抑制CD40信号的途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CARLOS S SUBAUSTE其他文献

CARLOS S SUBAUSTE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CARLOS S SUBAUSTE', 18)}}的其他基金

Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease
用于控制炎症性肠病的 CD40 信号小分子抑制剂
  • 批准号:
    10521673
  • 财政年份:
    2022
  • 资助金额:
    $ 35.42万
  • 项目类别:
Regulation of retinopathies
视网膜病变的调节
  • 批准号:
    8461196
  • 财政年份:
    2010
  • 资助金额:
    $ 35.42万
  • 项目类别:
Regulation of retinopathies
视网膜病变的调节
  • 批准号:
    8053324
  • 财政年份:
    2010
  • 资助金额:
    $ 35.42万
  • 项目类别:
Regulation of retinopathies
视网膜病变的调节
  • 批准号:
    7883716
  • 财政年份:
    2010
  • 资助金额:
    $ 35.42万
  • 项目类别:
Regulation of retinopathies
视网膜病变的调节
  • 批准号:
    8248326
  • 财政年份:
    2010
  • 资助金额:
    $ 35.42万
  • 项目类别:
Regulation of retinopathies
视网膜病变的调节
  • 批准号:
    10391449
  • 财政年份:
    2010
  • 资助金额:
    $ 35.42万
  • 项目类别:
Regulation of retinopathies
视网膜病变的调节
  • 批准号:
    9900008
  • 财政年份:
    2010
  • 资助金额:
    $ 35.42万
  • 项目类别:
Regulation of retinopathies
视网膜病变的调节
  • 批准号:
    10132320
  • 财政年份:
    2010
  • 资助金额:
    $ 35.42万
  • 项目类别:
Regulation of retinopathies
视网膜病变的调节
  • 批准号:
    8657046
  • 财政年份:
    2010
  • 资助金额:
    $ 35.42万
  • 项目类别:
Autophagy and Ocular Toxoplasmosis
自噬和眼弓形虫病
  • 批准号:
    10391468
  • 财政年份:
    2009
  • 资助金额:
    $ 35.42万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了